Clinical Trial Update: Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigates cryoablation combined with a PD-1 antibody and bevacizumab for hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: NOT_YET_RECRUITING